High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase

Table 2 Univariate and multivariate analyses for PFS and OS based on clinical and molecular variables

Variables	n	Univariate analyses						Multivariate analyses
		PFS			OS			PFS			OS
		HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Age ≤ 40 versus > 40	268 114/154	1.09	0.73–1.64	0.681	1.05	0.66–1.65	0.847	1.05	0.56–1.97	0.877	1.40	0.70–2.80	0.346
Sex Male versus female	268 152/116	1.18	0.79–1.78	0.434	1.01	0.64–1.58	0.977	1.85	1.00–3.42	0.050	1.21	0.61–2.40	0.590
Histopathology A* versus O	268 220/48	3.17	1.54–6.55	0.002	3.29	1.43–7.56	0.005	2.16	0.77–6.09	0.144	1.92	0.59–6.19	0.276
Seizure Yes versus no	204 122/82	0.70	0.47–1.05	0.086	0.64	0.41–1.01	0.055	0.85	0.46–1.57	0.605	0.87	0.44–1.73	0.686
Resection Total versus subtotal	248 115/133	0.59	0.38–0.92	0.018	0.75	0.46–1.20	0.229	0.85	0.45–1.61	0.615	0.88	0.43–1.81	0.729
Chemotherapy Yes versus no	260 87/173	1.53	1.02–2.31	0.039	0.96	0.59–1.67	0.875	1.49	0.82–2.73	0.195	0.94	0.46–1.94	0.867
Dose > 54 Gy versus ≤ 54 Gy	268 155/113	0.63	0.42–0.93	0.021	0.61	0.39–0.95	0.029	0.48	0.26–0.90	0.022	0.47	0.22–0.98	0.045
IDH mutation Yes versus no	250 206/44	0.61	0.37–1.00	0.049	0.64	0.37–1.12	0.12	0.51	0.26–0.98	0.044	0.44	0.21–0.96	0.038
1p/19q co-deletion Yes versus no	161 63/98	0.31	0.17–0.59	0.000	0.27	0.13–0.58	.001	0.42	0.18–0.96	0.039	0.42	0.16–1.12	0.082
MGMT pM Yes versus no	268 115/153	0.83	0.54–1.30	0.421	0.67	0.39–1.14	0.135	0.78	0.43–1.43	0.421	0.64	0.31–1.33	0.243

The significance were indicated by bold font
*A including astrocytoma and oligoastrocytoma which was eliminated in the 2016 WHO classification
PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval

ISSN: 1748-717X